Leaps by Bayer backs a protein engineering startup taking on Aimmune — and Nestlé — in peanut allergy

Amber Tong

Little capsules of peanut powder drove Nestlé’s $2.6 billion buyout of Aimmune. Now, with $40 million in new funding, a fledgling biotech is promising …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Leaps by Bayer backs a protein engineering startup taking on Aimmune — and Nestlé — in peanut allergy

Amber Tong

Sign up to read this article for free.

After stock slides, Amgen addresses bone density talk on obesity drug

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

Adaptimmune's second T cell receptor cell therapy for rare sarcomas passes pivotal test

New cancer class heats up as BioNTech buys out China partner and its PD-L1/VEGF drug

J&J takes 340B fight with federal government to court

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Leaps by Bay­er backs a pro­tein en­gi­neer­ing start­up tak­ing on Aim­mune — and Nestlé — in peanut al­ler­gy

Amber Tong

Sign up to read this article for free.

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

Adap­ti­m­mune's sec­ond T cell re­cep­tor cell ther­a­py for rare sar­co­mas pass­es piv­otal test

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

J&J takes 340B fight with fed­er­al gov­ern­ment to court

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Leaps by Bayer backs a protein engineering startup taking on Aimmune — and Nestlé — in peanut allergy

After stock slides, Amgen addresses bone density talk on obesity drug

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

Adaptimmune's second T cell receptor cell therapy for rare sarcomas passes pivotal test

New cancer class heats up as BioNTech buys out China partner and its PD-L1/VEGF drug

J&J takes 340B fight with federal government to court

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?